COMPARATIVE ACTIVITY OF AZITHROMYCIN AND DOXYCYCLINE AGAINST BRUCELLA SPP INFECTION IN MICE

被引:19
作者
DOMINGO, S
GASTEARENA, I
VITAS, AI
LOPEZGONI, I
DIOSVIEITEZ, C
DIAZ, R
GAMAZO, C
机构
[1] UNIV NAVARRA, DEPT MICROBIOL, E-31080 PAMPLONA, SPAIN
[2] UNIV NAVARRA, DEPT FARM & TECNOL FARMACEUT, E-31080 PAMPLONA, SPAIN
[3] UNIV NAVARRA CLIN, DEPT MICROBIOL, PAMPLONA, SPAIN
关键词
D O I
10.1093/jac/36.4.647
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The activities of a short therapeutic regimen with azithromycin and the classic treatment doxycycline with streptomycin were compared and evaluated in mice infected with Brucella melitensis. In a chronic model, starting therapy 31 days after challenge, azithromycin (10 days, 50 mg/kg/day) significantly reduced the infection (2.9 logs, day 48 post-infection). The effectiveness of doxycycline (21 days, 50 mg/kg/l2 hourly) was greater than azithromycin (4.1 logs of reduction, day 48 post-infection), and when doxycycline was administered for a period of 45 days, all the animals were bacteriologically cured from day 78. The combination with streptomycin (14 days, 10 mg/kg/day) did not improve the effect of any of the regimens. In an acute model infection, treatments with doxycycline or doxycycline-streptomycin, for a period of 3 days, starting 1 day after lethal challenge, were able to protect all the mice. In contrast, only 50% of the mice treated with azithromycin survived the challenge. In conclusion, although a short oral treatment with azithromycin was able to reduce the infection significantly, it was not able to cure the animals as effectively as the classic regimen with doxycycline administered for a longer period of time.
引用
收藏
页码:647 / 656
页数:10
相关论文
共 25 条
[1]  
Alton G.C., 1988, TECHNIQUES BRUCELLOS
[2]   RELEVANCE OF INVITRO ANTIMICROBIAL SUSCEPTIBILITY OF BRUCELLA-MELITENSIS TO RELAPSE RATE IN HUMAN BRUCELLOSIS [J].
ARIZA, J ;
BOSCH, J ;
GUDIOL, F ;
LINARES, J ;
VILADRICH, PF ;
MARTIN, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (06) :958-960
[3]   TREATMENT OF HUMAN BRUCELLOSIS WITH DOXYCYCLINE PLUS RIFAMPIN OR DOXYCYCLINE PLUS STREPTOMYCIN - A RANDOMIZED, DOUBLE-BLIND-STUDY [J].
ARIZA, J ;
GUDIOL, F ;
PALLARES, R ;
VILADRICH, PF ;
RUFI, G ;
CORREDOIRA, J ;
MIRAVITLLES, MR .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (01) :25-30
[4]   COMPARATIVE TRIAL OF RIFAMPIN-DOXYCYCLINE VERSUS TETRACYCLINE-STREPTOMYCIN IN THE THERAPY OF HUMAN BRUCELLOSIS [J].
ARIZA, J ;
GUDIOL, F ;
PALLARES, R ;
RUFI, G ;
FERNANDEZVILADRICH, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (04) :548-551
[5]   QUALITY-CONTROL PARAMETERS AND INTERPRETIVE CRITERIA FOR INVITRO SUSCEPTIBILITY TESTS WITH THE MACROLIDE AZITHROMYCIN [J].
BARRY, AL ;
THORNSBERRY, C ;
GAVAN, TL .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (06) :544-549
[6]   INVITRO ACTIVITIES OF AZITHROMYCIN (CP-62,993), CLARITHROMYCIN (A-56268-TE-031), ERYTHROMYCIN, ROXITHROMYCIN, AND CLINDAMYCIN [J].
BARRY, AL ;
JONES, RN ;
THORNSBERRY, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :752-754
[7]  
CASTILLO JDC, 1989, CHEMOTHERAPY, V35, P146
[8]  
Domingo S, 1995, J CHEMOTHERAPY, V7, P29
[9]  
Feiz J M, 1973, Br J Clin Pract, V27, P410
[10]   INVITRO ACTIVITIES OF NEW MACROLIDES AND RIFAPENTINE AGAINST BRUCELLA SPP [J].
GARCIARODRIGUEZ, JA ;
BELLIDO, JLM ;
FRESNADILLO, MJ ;
TRUJILLANO, I .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :911-913